Key result
A combined regimen of intracoronary urokinase and intravenous abciximab successfully achieved complete resolution of coronary emboli in a patient with prosthetic heart valves.
Why the study?
Does a combined regimen of intracoronary urokinase and intravenous abciximab resolve coronary embolism in a patient with mechanical valve replacements?
Population
1 63-year-old woman with St. Jude aortic and mitral valve replacements presenting with acute myocardial…
Design
Case_report
Authors
Loading...
May support combined therapy in refractory valve-related embolism; leaves open need for prospective validation before broader use.
Case Report (n=1)
Does a combined regimen of intracoronary urokinase and intravenous abciximab resolve coronary embolism in a patient with mechanical valve replacements?
A combined regimen of intracoronary urokinase and intravenous abciximab can successfully treat coronary embolism in patients with mechanical heart valves.
Quinn et al. (1998) conducted a case report in Coronary embolism and acute myocardial infarction (n=1). Intracoronary urokinase and intravenous abciximab was evaluated on Resolution of emboli. A combined regimen of intracoronary urokinase and intravenous abciximab successfully achieved complete resolution of coronary emboli in a patient with prosthetic heart valves.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: